Ultragenyx Pharmaceutical (RARE) Research & Development (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) reported Research & Development of $187.0 million for Q1 2026, up 12.65% year-over-year from $166.0 million in Q1 2025, and down 8.01% on a QoQ basis from $203.3 million in Q4 2025.
Ultragenyx Pharmaceutical (RARE) has 14 years of Research & Development data on file, last reported at $187.0 million in Q1 2026.
- Quarterly Research & Development rose 12.65% year-over-year to $187.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $771.2 million (up 12.5% YoY) and the FY2025 annual result came in at $750.0 million, up 7.45% from the prior year.
- Research & Development eased to $187.0 million in Q1 2026 per RARE's latest filing, from $203.3 million in the prior quarter.
- Across five years, Research & Development topped out at $237.3 million in Q3 2022 and bottomed at $143.2 million in Q1 2022.
- The 5-year median for Research & Development is $166.0 million (2025), against an average of $175.8 million.
- The widest annual swing landed in 2022, when Research & Development jumped 109.23%; it then slumped 33.73% in 2023.
- Tracing RARE's Research & Development over 5 years: stood at $170.8 million in 2022, then retreated by 6.26% to $160.1 million in 2023, then advanced by 17.36% to $187.9 million in 2024, then climbed by 8.18% to $203.3 million in 2025, then slipped by 8.01% to $187.0 million in 2026.
- Per Business Quant, the three latest RARE Research & Development figures stand at $187.0 million (Q1 2026), $203.3 million (Q4 2025), and $216.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | 187.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 187.00 Mn |
| Dec 31, 2025 | 203.28 Mn |
| Sep 30, 2025 | 216.21 Mn |
| Jun 30, 2025 | 164.74 Mn |
| Mar 31, 2025 | 166.00 Mn |
| Dec 31, 2024 | 187.90 Mn |
| Sep 30, 2024 | 170.11 Mn |
| Jun 30, 2024 | 161.50 Mn |
| Mar 31, 2024 | 178.49 Mn |
| Dec 31, 2023 | 160.11 Mn |
| Sep 30, 2023 | 157.25 Mn |
| Jun 30, 2023 | 164.95 Mn |
| Mar 31, 2023 | 165.70 Mn |
| Dec 31, 2022 | 170.81 Mn |
| Sep 30, 2022 | 237.30 Mn |
| Jun 30, 2022 | 154.53 Mn |
| Mar 31, 2022 | 143.16 Mn |
| Dec 31, 2021 | 123.01 Mn |
| Sep 30, 2021 | 113.42 Mn |
| Jun 30, 2021 | 113.21 Mn |
| Mar 31, 2021 | 147.52 Mn |
| Dec 31, 2020 | 131.10 Mn |
| Sep 30, 2020 | 87.31 Mn |
| Jun 30, 2020 | 80.71 Mn |
| Mar 31, 2020 | 25.00 Mn |
| Dec 31, 2019 | 83.06 Mn |
| Sep 30, 2019 | 100.14 Mn |
| Jun 30, 2019 | 6.00 Mn |
| Mar 31, 2019 | 78.11 Mn |
| Dec 31, 2018 | 71.62 Mn |
| Sep 30, 2018 | 70.04 Mn |
| Jun 30, 2018 | 76.84 Mn |
| Mar 31, 2018 | 75.50 Mn |
| Dec 31, 2017 | 1.00 Mn |
| Sep 30, 2017 | 60.41 Mn |
| Jun 30, 2017 | 58.44 Mn |
| Mar 31, 2017 | 51.27 Mn |
| Dec 31, 2016 | 50.75 Mn |
| Sep 30, 2016 | 48.71 Mn |
| Jun 30, 2016 | 43.33 Mn |
| Mar 31, 2016 | 40.42 Mn |
| Dec 31, 2015 | 44.57 Mn |
| Sep 30, 2015 | 29.70 Mn |
| Jun 30, 2015 | 23.10 Mn |
| Mar 31, 2015 | 17.36 Mn |
| Dec 31, 2014 | 13.52 Mn |
| Sep 30, 2014 | 12.85 Mn |
| Jun 30, 2014 | 11.24 Mn |
| Mar 31, 2014 | 8.35 Mn |
| Dec 31, 2013 | 8.20 Mn |
| Sep 30, 2013 | 6.76 Mn |
| Jun 30, 2013 | 7.20 Mn |
| Mar 31, 2013 | 5.66 Mn |